Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
作者信息
James Morgan H, Fragale Jennifer E, Aurora R Nisha, Cooperman Nina A, Langleben Daniel D, Aston-Jones Gary
机构信息
Brain Health Institute, Rutgers University, Piscataway, NJ, USA.
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
出版信息
Neuropsychopharmacology. 2020 Apr;45(5):717-719. doi: 10.1038/s41386-020-0619-x. Epub 2020 Jan 27.
Abstract
摘要
相似文献
1
Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?将双重食欲素受体拮抗剂苏沃雷生重新用于治疗阿片类物质使用障碍：为何还要对此拖延？
Neuropsychopharmacology. 2020 Apr;45(5):717-719. doi: 10.1038/s41386-020-0619-x. Epub 2020 Jan 27.
2
Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.苏沃雷生治疗酒精使用障碍及共病性失眠：一项 II 期试验计划。
Brain Res. 2020 Feb 1;1728:146597. doi: 10.1016/j.brainres.2019.146597. Epub 2019 Dec 11.
3
A sleeping giant: Suvorexant for the treatment of alcohol use disorder?沉睡的巨人：苏沃雷生治疗酒精使用障碍？
Brain Res. 2020 Mar 15;1731:145902. doi: 10.1016/j.brainres.2018.08.005. Epub 2018 Aug 3.
4
Suvorexant: first global approval.苏沃雷生：全球首次批准。
Drugs. 2014 Oct;74(15):1817-22. doi: 10.1007/s40265-014-0294-5.
5
[Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].新型失眠治疗药物双食欲素受体拮抗剂苏沃雷生（BELSOMRA(®)）的临床前及临床研究结果
Nihon Yakurigaku Zasshi. 2016 Jul;148(1):46-56. doi: 10.1254/fpj.148.46.
6
Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders.食欲素在睡眠障碍和与生活方式相关疾病中的时病理生理学意义。
Pharmacol Ther. 2018 Jun;186:25-44. doi: 10.1016/j.pharmthera.2017.12.010. Epub 2017 Dec 29.
7
Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.苏沃雷生：一种双重食欲素受体拮抗剂治疗失眠的疗效和安全性概况。
Drugs Today (Barc). 2016 Jan;52(1):29-40. doi: 10.1358/dot.2016.52.1.2439940.
8
Suvorexant (Belsomra) for insomnia.苏沃雷生（Belsomra）用于治疗失眠。
Med Lett Drugs Ther. 2015 Mar 2;57(1463):29-31.
9
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.食欲素受体拮抗剂治疗失眠及潜在的其他神经精神适应证治疗。
J Sleep Res. 2019 Apr;28(2):e12782. doi: 10.1111/jsr.12782. Epub 2018 Oct 18.
10
Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder.初步研究可卡因使用障碍复发相关因素中的食欲素系统。
Brain Res. 2020 Mar 15;1731:146359. doi: 10.1016/j.brainres.2019.146359. Epub 2019 Jul 30.
引用本文的文献
1
Sleep Loss and Substance Use Disorders: An Issue from Adolescents to Adults.睡眠不足与物质使用障碍：从青少年到成年人的一个问题。
Behav Sci (Basel). 2025 Feb 15;15(2):220. doi: 10.3390/bs15020220.
2
Preliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study.使用苏沃雷生对甲基苯丙胺使用障碍个体进行食欲素受体拮抗作用的初步研究：一项病例系列研究。
J Addict Dis. 2024 Dec 28:1-8. doi: 10.1080/10550887.2024.2434298.
3
Emerging medications and pharmacological treatment approaches for substance use disorders.物质使用障碍的新兴药物及药物治疗方法。
Pharmacol Biochem Behav. 2025 Mar;248:173952. doi: 10.1016/j.pbb.2024.173952. Epub 2024 Dec 22.
4
An emerging multi-omic understanding of the genetics of opioid addiction.阿片类药物成瘾遗传学的新兴多组学研究。
J Clin Invest. 2024 Oct 15;134(20):e172886. doi: 10.1172/JCI172886.
5
Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation.下丘脑食欲素（Hypocretin）回路对动机相关疾病的影响。
Br J Pharmacol. 2024 Nov;181(22):4430-4449. doi: 10.1111/bph.17325. Epub 2024 Sep 24.
6
Suvorexant enhances oxycodone-induced respiratory depression in male rats.苏沃雷生增强了雄性大鼠体内羟考酮诱发的呼吸抑制。
Drug Alcohol Depend. 2024 Nov 1;264:112434. doi: 10.1016/j.drugalcdep.2024.112434. Epub 2024 Sep 6.
7
Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder.接受丁丙诺啡治疗阿片类物质使用障碍的成年人的失眠症状及其神经功能相关性。
PLoS One. 2024 Jun 13;19(6):e0304461. doi: 10.1371/journal.pone.0304461. eCollection 2024.
8
Machine learning models to predict ligand binding affinity for the orexin 1 receptor.用于预测食欲素1受体配体结合亲和力的机器学习模型。
Artif Intell Chem. 2024 Jun;2(1). doi: 10.1016/j.aichem.2023.100040. Epub 2023 Dec 20.
9
IUPHAR Review: New strategies for medications to treat substance use disorders.IUPHAR 评论：治疗物质使用障碍的药物新策略。
Pharmacol Res. 2024 Feb;200:107078. doi: 10.1016/j.phrs.2024.107078. Epub 2024 Jan 20.
10
Recent advances in drug discovery efforts targeting the sigma 1 receptor system: Implications for novel medications designed to reduce excessive drug and food seeking.针对σ1受体系统的药物研发新进展：对旨在减少过度药物和食物寻求行为的新型药物的启示
Addict Neurosci. 2023 Dec;8. doi: 10.1016/j.addicn.2023.100126. Epub 2023 Aug 27.
Zotero 插件